{"id":50627,"date":"2025-03-18T20:09:09","date_gmt":"2025-03-18T20:09:09","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=50627"},"modified":"2025-03-20T22:38:34","modified_gmt":"2025-03-20T22:38:34","slug":"croi-2025-ensitrelvir-significantly-reduces-risk-of-developing-covid-19-after-household-exposure","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/50627","title":{"rendered":"CROI 2025: Ensitrelvir significantly reduces risk of developing COVID-19 after household exposure"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>An oral presentation of the phase 3 SCORPIO-PEP study supported using the protease inhibitor ensitrelvir as PEP to prevent COVID-19 in household settings. It is already approved in Japan for treatment of mild to moderate COVID-19.<\/strong><\/p>\n<p>Index cases needed to have tested positive and be symptomatic. Nearly 24,000 household contacts were randomised to a 50-day course of ensitrelvir or placebo within three days of symptom onset in the index case.<\/p>\n<p>Approximate baseline demographics includes median age 42 (with 10% over 65), just over half were women and median BMI was 26. Approximately two-thirds enrolled in the US and one quarter in Japan, with about 70% enrolling within 48 hours of symptom onset in the index case and &gt;99% were seropositive.<\/p>\n<p>Ensitrelvir was associated with a highly significantly reduced risk of COVID-19 by day 10: 2.9% vs 9.0% with a risk ratio of 0.33 (95%CI: 0.22 to 0.49), p &lt;0.0001.<\/p>\n<p>Tolerability in the study was generally good with no new safety concerns.<\/p>\n<p>Reference<\/p>\n<p>Fukushi A et al for the SCORPIO-PEP Study Team. Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP. CROI 2025. Oral abstract 200.<br \/>\n<a href=\"https:\/\/www.croiconference.org\/abstract\/3747-2025\/\">www.croiconference.org\/abstract\/3747-2025 <\/a>(abstract)<br \/>\n<a href=\"https:\/\/watch.croiwebcasts.org\/2025croi\/ap\/54366\">watch.croiwebcasts.org\/2025croi\/ap\/54366<\/a> (webcast for delegates)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base An oral presentation of the phase 3 SCORPIO-PEP study supported using the protease inhibitor ensitrelvir as PEP to prevent COVID-19 in household settings. It is already approved in Japan for treatment of mild to moderate COVID-19. &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,278],"tags":[339],"class_list":["post-50627","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-covid-19","tag-croi-2025"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=50627"}],"version-history":[{"count":7,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50627\/revisions"}],"predecessor-version":[{"id":50646,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50627\/revisions\/50646"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=50627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=50627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=50627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}